

COVID-19 Vaccine Update

Webinar 4

Date: December 20th, 2022

Presentation By:

Allie Staton, PharmD

Vaccine Confidence Strategist

Immunize Arkansas

Email: allie@immunizear.org



UAMS DISCLOSURE POLICY

It is the policy of the University of Arkansas for Medical Sciences (UAMS) to ensure balance, independence, objectivity, and scientific rigor in all directly or jointly provided educational activities.

All individuals who are in a position to control the content of the educational activity (course/activity directors, planning committee members, staff, teachers, or authors of CE) must disclose all relevant financial relationships they have with any commercial interest(s) as well as the nature of the relationship. The ACCME and ACPE describe relevant financial relationships as those in any amount occurring within the past 24 months that create a conflict of interest. *Individuals who refuse to disclose will be disqualified from participation in the development, management, presentation, or evaluation of the CE activity.*

DISCLOSURES

The following planners and speakers of this CE activity have no relevant financial relationships with ineligible companies to disclose:

Allie Staton, PharmD

The accreditation compliance reviewers, Courtney Bryant and Sara Hale, have no relevant financial relationships with ineligible companies to disclose.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



CREDIT DESIGNATION STATEMENTS

AMA Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit Designation Statement

These knowledge based activities will provide pharmacists up to 1.0 contact hours or 0.1 CEU. CE credit information, based on verification of live attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion.

ANCC Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 ANCC contact hours. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials.

AAPA Credit Designation Statement

The University of Arkansas for Medical Sciences has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

CONTINUING EDUCATION

To receive Continuing Education:

- **You must attend this webinar as it is being presented.**
 - Attendance will be recorded via Zoom to determine if you were present.
 - If you are watching this as a recording, you will not be eligible to receive CE.
- **You must complete the Evaluation Survey following this webinar.**
 - A link to the Evaluation Survey will be posted in the chat at the end of the presentation.
 - **DEADLINE: Midnight on Wednesday, December 21st**
 - **No late evaluations will be accepted.** Please complete the survey ASAP.
 - The survey link will also be sent out tomorrow in a follow-up email.
- **Certificates of Completion for attending this course will be available after you complete the Evaluation Survey.**
 - There will be a link provided at the end of the Evaluation Survey to access the Certificates of Completion.
 - You will have to write your name on the Certificate.
 - A link to the Certificates of Completion will also be sent out tomorrow in a follow-up email.

WEBINAR

- If you have a question during the webinar, please post your question in the chat.
 - We will do our best to answer all questions before the end of the webinar.
- If you have a question after the webinar, please email Allie Staton.
 - allie@immunizear.org

OBJECTIVES

At the end of this webinar, learners will be able to:

- Interpret current COVID-19 vaccine guidelines.
- Recommend appropriate vaccines to patients and community members.
- Discuss current COVID-19 vaccine guidelines and recommendations.

TOPICS

- Review new pediatric bivalent COVID-19 vaccines
- Review current COVID-19 vaccine booster recommendations
- Discuss commonly asked questions

CDC INTERIM CLINICAL CONSIDERATIONS FOR COVID-19 VACCINES

COVID-19 vaccine recommendations are based on:

- Age
- Health Status
 - Healthy versus Moderately to Severely Immunocompromised
- Previous doses of COVID-19 vaccines

Recommendations for use of COVID-19 vaccines are published on the CDC's website.

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

CURRENTLY AVAILABLE PRODUCTS

COVID-19 VACCINE PRODUCT REVIEW

Pfizer	Moderna	Janssen / J&J	Novavax
mRNA	mRNA	Adenovirus Vector	Protein Subunit
6 months and older	6 months and older	18 years and older	12 years and older
<p><u>Products</u> Monovalent:</p> <ul style="list-style-type: none"> - 6 months thru 4 years - 5 years thru 11 years - 12 years and older <p>Bivalent:</p> <ul style="list-style-type: none"> - 6 months thru 4 years - 5 years thru 11 years - 12 years and older 	<p><u>Products</u> Monovalent:</p> <ul style="list-style-type: none"> - 6 months thru 5 years - 6 years thru 11 years - 12 years and older <p>Bivalent:</p> <ul style="list-style-type: none"> - 6 months thru 5 years - 6 years and older <p>*half-dose for 6 years thru 11 years</p>	<p><u>Products</u> Monovalent:</p> <ul style="list-style-type: none"> - 18 years and older 	<p><u>Products</u> Monovalent:</p> <ul style="list-style-type: none"> - 12 years and older

PFIZER / BIONTECH

	Pfizer Monovalent			Pfizer Bivalent		
	Pfizer Primary Series	Pfizer Primary Series	Pfizer Primary Series	Pfizer Bivalent Primary Series (3 rd dose only)	Pfizer Bivalent Booster	Pfizer Bivalent Booster
Age Group	6 months thru 4 years	5 years thru 11 years	12 years and older	6 months thru 4 years	5 years thru 11 years	12 years and older
Vial Cap and Label color	Cap: Maroon Label Border: Maroon	Cap: Orange Label Border: Orange	Cap: Gray Label Border: Gray	Cap: Maroon Label Border: Maroon	Cap: Orange Label Border: Orange	Cap: Gray Label Border: Gray
Dilution?	YES (2.2 mL)	YES (1.3 mL)	NO	YES (2.2 mL)	YES (1.3 mL)	NO
Dose Volume	0.2 mL	0.2 mL	0.3 mL	0.2 mL	0.2 mL	0.3 mL
Doses per Vial	10	10	6	10	10	6
Expiration	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours

Disclaimer: The information in this chart is subject to change. Please see current Fact Sheets for Healthcare Providers for updated information.

MODERNA

	Moderna Monovalent			Moderna Bivalent	
	Moderna Primary Series	Moderna Primary Series	Moderna Primary Series	Moderna Bivalent Booster	Moderna Bivalent Booster
Age Group	6 months thru 5 years	6 years thru 11 years	12 years and older	6 months thru 5 years	6 years and older
Vial Cap and Label color	Cap: Blue Label Border: Magenta	Cap: Blue Label Border: Purple	Cap: Red Label Border: Blue	Cap: Dark Pink Label Border: Yellow	Cap: Blue Label Border: Gray
Dilution?	NO	NO	NO	NO	NO
Dose Volume	0.25 mL	0.5 mL	0.5 mL	0.2 mL	6 – 11 years: 0.25 mL 12 years and older: 0.5 mL
Doses per Vial	10	5	11	2	5
Expiration	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 8 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours

Disclaimer: The information in this chart is subject to change. Please see current Fact Sheets for Healthcare Providers for updated information.

JANSSEN / JOHNSON & JOHNSON

	J&J Primary Series
Age Group	18 years and older
Dilution?	NO
Dose Volume	0.5 mL
Doses per Vial	5
Expiration	UCF: NA Freezer: NA Fridge: Good until exp date Room Temp: 12 hours After Puncture: 6 hours in fridge, or 2 hours at room temp

J&J should only be used in certain situations.

Pfizer, Moderna, and Novavax are all preferred over J&J.

WARNING: Thrombosis with Thrombocytopenia Syndrome

- COVID-19 vaccine providers must counsel on this risk before administration of J&J.
- See EUA for more information.



NOVAVAX

	Novavax Primary Series	Novavax Booster Dose (same product as primary series)
Age Group	12 years and older	18 years and older
Dilution?	NO	NO
Dose Volume	0.5 mL	0.5 mL
Doses per Vial	10	10
Expiration	UCF: NA Freezer: NA Fridge: Good until exp date Room Temp: NA After Puncture: 6 hours in fridge, or 6 hours at room temp	UCF: NA Freezer: NA Fridge: Good until exp date Room Temp: NA After Puncture: 6 hours in fridge, or 6 hours at room temp

Novavax has a mechanism that is similar to vaccines that have been approved for years.

This vaccine is an option for those who are hesitant about the mRNA technology that was used for the other COVID-19 vaccines.

**See next slide for Booster
Dose Eligibility**

Use of the monovalent Novavax booster dose in limited situations

- People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine **and have not received any previous booster dose(s)** may receive a monovalent Novavax booster dose **at least 6 months after completion of the primary series** if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

Novavax Booster Eligibility:

- 18 years or older
- Completed primary series of a monovalent product
- 6 months since last dose of primary series
- No booster doses of an mRNA product
- Unable or unwilling to receive an mRNA bivalent booster

CURRENT RECOMMENDATIONS

COVID-19 Vaccine Recommendations

Booster Doses

Date: December 9, 2022



Everyone ages 5 years and older is recommended to receive ONE age-appropriate bivalent mRNA booster dose at least 2 months after completion of any FDA-approved or FDA-authorized monovalent primary series *or* last monovalent booster dose.

Patients ages 6 months thru 4 years *may* be eligible for a bivalent booster (see below).

Vaccination History	→	Next dose
Primary series	At least 2 months →	1 bivalent booster dose
Primary series + 1 booster	At least 2 months →	1 bivalent booster dose
Primary series + 2 boosters	At least 2 months →	1 bivalent booster dose

- Fall Booster “Reset” → moving forward, recommendations will be simplified.
 - Change from “dose counting” (ex. dose 4, dose 5, etc.) to ONE bivalent booster for everyone eligible.
- Monovalent vaccine products must still be used for **primary series** doses.
- Monovalent vaccine products are **no longer authorized for use as booster doses** for patients 6 months and older.
 - EXCEPTION: Novavax (monovalent) can be used as a booster dose for patients 18 years and older in very specific situations.
 - Patients must have not received an mRNA booster dose (either monovalent or bivalent) to be eligible.
- Age-appropriate homologous and heterologous boosters are allowed; there is no preference.
 - EXCEPTION: Patients ages 6 months thru 4 years who completed a primary series of Pfizer are NOT eligible for any bivalent booster product at this time.

Moderna: Ages 6 months thru 5 years

- Patients ages 6 months thru 5 years who received a Moderna primary series are eligible for a Moderna Bivalent Booster (pink cap).

Pfizer: Ages 6 months thru 4 years

- Patients ages 6 months thru 4 years who completed a Pfizer primary series are NOT eligible for a bivalent booster.
 - If a patient has not yet received their 3rd dose of the primary series, they should receive Pfizer Bivalent (maroon cap) as their 3rd dose.
 - If a patient has already received their 3rd dose of the primary series, they should NOT receive any bivalent product as a booster dose.
 - They are NOT eligible to receive Moderna Bivalent as a booster.

Bivalent Products	Age	Volume	Booster?
Pfizer Bivalent (maroon cap)	6 mo – 4 years	0.2 mL	Dose 3 (primary series)
Pfizer Bivalent (orange cap)	5 – 11 years	0.2 mL	Booster
Pfizer Bivalent (gray cap)	12 years and older	0.3 mL	Booster
Moderna Bivalent (pink cap, yellow label)	6 mo – 5 years	0.2 mL	Booster
Moderna Bivalent (blue cap, gray label)	6 – 11 years	0.25 mL	Booster
	12 years and older	0.5 mL	Booster

COVID-19 Vaccine Recommendations

Healthy Adults: Administration of Primary Series and Booster Doses (ages 18 and older)

Date: December 9, 2022



PRIMARY SERIES (monovalent products only)				BOOSTER DOSES (bivalent products only)	
	Dose 1		Dose 2	Booster	
Pfizer Cap: Gray or Purple	(primary) Pfizer Monovalent: 0.3 mL	Wait 3 – 8 weeks →	(primary) Pfizer Monovalent: 0.3 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
Moderna Cap: Red	(primary) Moderna Monovalent: 0.5 mL	Wait 4 – 8 weeks →	(primary) Moderna Monovalent: 0.5 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
Novavax	(primary) Novavax Monovalent: 0.5 mL	Wait 3 – 8 weeks →	(primary) Novavax Monovalent: 0.5 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
J & J J&J should only be used in limited situations	(primary) J&J Monovalent: 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL

See Child and Adolescent charts for recommendations for those under 18 years of age

Please see CDC Interim Clinical Considerations for official guidance.

COVID-19 Vaccine Recommendations

Immunocompromised Adults: Administration of Primary Series and Booster Doses (ages 18 and older)

Date: December 9, 2022



PRIMARY SERIES (monovalent products only)						BOOSTER DOSES (bivalent products only)	
	Dose 1		Dose 2		Dose 3	Booster	
Pfizer Cap: Gray or Purple	(primary) Pfizer Monovalent: 0.3 mL	Wait 3 weeks →	(primary) Pfizer Monovalent: 0.3 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> Pfizer Monovalent: 0.3 mL OR Moderna Monovalent: 0.5 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	(primary) Moderna Monovalent: 0.5 mL	Wait 4 weeks →	(primary) Moderna Monovalent: 0.5 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> Pfizer Monovalent: 0.3 mL OR Moderna Monovalent: 0.5 mL		
Novavax	(primary) Novavax Monovalent: 0.5 mL	Wait 3 weeks →	(primary) Novavax Monovalent: 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
J & J J&J should only be used in limited situations	(primary) J&J Monovalent: 0.5 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> Pfizer Monovalent: 0.3 mL OR Moderna Monovalent: 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL

See Child and Adolescent charts for recommendations for those under 18 years of age

Please see CDC Interim Clinical Considerations for official guidance.

www.immunizear.org

COVID-19 Vaccine Recommendations

Healthy Children and Adolescents: Administration of Primary Series and Booster Doses (ages 6 months through 17 years)

Date: December 9, 2022



PRIMARY SERIES						BOOSTER DOSES (bivalent products only)	
Row Color = Cap Color	Dose 1		Dose 2		Dose 3	Booster	
Pfizer Cap: Maroon Age: 6 mo – 4 years	(primary) 0.2 mL	Wait 3 – 8 weeks →	(primary) 0.2 mL	Wait 8 weeks →	(primary) *BIVALENT* 0.2 mL	No boosters are recommended for this age group if patient received a Pfizer primary series. <ul style="list-style-type: none"> Pfizer (maroon cap) BIVALENT product should be used for Dose 3 in the primary series for this age group. If a patient in this age group has already received the monovalent product for Dose 3, they are NOT eligible to receive a dose of a bivalent product at this time. 	
Pfizer Cap: Orange Age: 5 – 11 years	(primary) 0.2 mL	Wait 3 – 8 weeks →	(primary) 0.2 mL			Wait 2 months →	Pfizer Bivalent (orange cap): 0.2 mL OR Moderna Bivalent (pink cap): 0.2 mL <i>*Only for age 5 years (if Pfizer was primary series)</i> OR Moderna Bivalent (blue cap): 0.25 mL <i>*Age 6 years – 11 years</i>
Pfizer Cap: Gray or Purple Age: 12 – 17 years (same vaccine product for 18 years and older)	(primary) 0.3 mL	Wait 3 – 8 weeks →	(primary) 0.3 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent (gray cap): 0.3 mL OR Moderna Bivalent (blue cap): 0.5 mL
Row Color = Label Color	Dose 1		Dose 2			Booster	
Moderna Cap: Dark Blue Label: Magenta Age: 6 mo – 5 years	(primary) 0.25 mL	Wait 4 – 8 weeks →	(primary) 0.25 mL			Wait 2 months →	Moderna Bivalent (pink cap): 0.2 mL
Moderna Cap: Dark Blue Label: Purple Age: 6 – 11 years	(primary) 0.5 mL	Wait 4 – 8 weeks →	(primary) 0.5 mL			Wait 2 months →	Pfizer Bivalent (orange cap): 0.2 mL OR Moderna Bivalent (blue cap): 0.25 mL
Moderna Cap: Red Label: Light Blue Age: 12 – 17 years (same vaccine product for 18 years and older)	(primary) 0.5 mL	Wait 4 – 8 weeks →	(primary) 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent (gray cap): 0.3 mL OR Moderna Bivalent (blue cap): 0.5 mL
	Dose 1		Dose 2			Booster	
Novavax Age: 12 – 17 years (same vaccine product for 18 years and older)	(primary) 0.5 mL	Wait 3 – 8 weeks →	(primary) 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent (gray cap): 0.3 mL OR Moderna Bivalent (blue cap): 0.5 mL

Moderna Purple Label says “Booster Dose Only”. It CANNOT be used for booster doses anymore.

Please see CDC Interim Clinical Considerations for official guidance.

COVID-19 Vaccine Recommendations

Immunocompromised Children and Adolescents: Administration of Primary Series and Booster Doses (ages 6 months through 17 years)

Date: December 9, 2022



PRIMARY SERIES						BOOSTER DOSES (bivalent products only)	
Row Color = Cap Color	Dose 1		Dose 2		Dose 3	Booster	
Pfizer Cap: Maroon Age: 6 mo – 4 years	(primary) 0.2 mL	Wait 3 weeks →	(primary) 0.2 mL	Wait 8 weeks →	(primary) *BIVALENT* 0.2 mL	No boosters are recommended for this age group if patient received a Pfizer primary series. <ul style="list-style-type: none"> Pfizer (maroon cap) BIVALENT product should be used for Dose 3 in the primary series for this age group. If a patient in this age group has already received the monovalent product for Dose 3, they are NOT eligible to receive a dose of a bivalent product at this time. 	
Pfizer Cap: Orange Age: 5 – 11 years	(primary) 0.2 mL	Wait 3 weeks →	(primary) 0.2 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.2 mL	Wait 2 months →	Pfizer Bivalent (orange cap): 0.2 mL OR Moderna Bivalent (pink cap): 0.2 mL <i>*Only for age 5 years (if Pfizer was primary series)</i> OR Moderna Bivalent (blue cap): 0.25 mL <i>*Age 6 years – 11 years</i>
Pfizer Cap: Gray or Purple Age: 12 – 17 years (same vaccine product for 18 years and older)	(primary) 0.3 mL	Wait 3 weeks →	(primary) 0.3 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.3 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent (gray cap): 0.3 mL OR Moderna Bivalent (blue cap): 0.5 mL
Row Color = Label Color	Dose 1		Dose 2		Dose 3	Booster	
Moderna Cap: Dark Blue Label: Magenta Age: 6 mo – 5 years	(primary) 0.25 mL	Wait 4 weeks →	(primary) 0.25 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.25 mL	Wait 2 months →	Moderna Bivalent (pink cap): 0.2 mL
Moderna Cap: Dark Blue Label: Purple Age: 6 – 11 years	(primary) 0.5 mL	Wait 4 weeks →	(primary) 0.5 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.5 mL	Wait 2 months →	Pfizer Bivalent (orange cap): 0.2 mL OR Moderna Bivalent (blue cap): 0.25 mL
Moderna Cap: Red Label: Light Blue Age: 12 – 17 years (same vaccine product for 18 years and older)	(primary) 0.5 mL	Wait 4 weeks →	(primary) 0.5 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.5 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent (gray cap): 0.3 mL OR Moderna Bivalent (blue cap): 0.5 mL
Novavax Age: 12 – 17 years (same vaccine product for 18 years and older)	(primary) 0.5 mL	Wait 3 weeks →	(primary) 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent (gray cap): 0.3 mL OR Moderna Bivalent (blue cap): 0.5 mL

Moderna Purple Label says “Booster Dose Only”. It CANNOT be used for booster doses anymore.

Use of the monovalent Novavax booster dose in limited situations

- People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine **and have not received any previous booster dose(s)** may receive a monovalent Novavax booster dose **at least 6 months after completion of the primary series** if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

COMMON QUESTIONS
&
SCENARIOS

QUESTIONS

If my 3 year old received a complete primary series (3 doses) of Pfizer, are they eligible for a booster?

- NO.
- At this time, there is no booster dose recommendation for children ages 6 months thru 4 years who received a complete primary series of Pfizer.

QUESTIONS

If my 3 year old received 2 doses of Pfizer, are they eligible for a booster?

- This is not considered a “booster.”
- However, the patient IS eligible for their 3rd dose of their primary series if it has been at least 8 weeks since their second dose.
- This patient should receive the bivalent Pfizer maroon cap product.

QUESTIONS

If my 3 year old received a complete primary series (2 doses) of Moderna are they eligible for a booster?

- YES, if it has been at least 2 months since their last dose.

QUESTIONS

Can I administer a Novavax booster to a patient who received 2 doses of Pfizer?

- Yes, if they meet ALL the criteria below.

Novavax Booster Eligibility:

- 18 years or older
- Completed primary series of a monovalent product
- 6 months since last dose of primary series
- No booster doses of an mRNA product
- Unable or unwilling to receive an mRNA bivalent booster

QUESTIONS

What do we do if we administer a bivalent booster and the patient has not completed a primary series?

- Use this chart in the CDC Interim Clinical Considerations for guidance on any vaccine administration errors with COVID-19 vaccines.
 - <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-d>

<ul style="list-style-type: none">• Bivalent vaccine incorrectly administered for the primary series	<ul style="list-style-type: none">• Bivalent Pfizer-BioNTech vaccine: Do not repeat dose.• Bivalent Moderna vaccine: Repeat 1 monovalent dose immediately (no minimum interval)[§] because administration of the booster dose will result in a lower-than-authorized dose.
--	--

QUESTIONS

If someone has received either all Pfizer or all Moderna, is there a preference on which new booster product they should receive?

- NO.
- There is no official recommendation or preference for either Pfizer or Moderna.

QUESTIONS

If someone received one dose of Moderna or Pfizer but never received a second dose, can they get the new bivalent booster?

- NO.
- Patients must complete a primary series before they are eligible to receive a bivalent booster dose.

QUESTIONS

If someone decides they want the flu shot before the COVID-19 booster, how long do they need to wait before they can get the COVID-19 booster?

- There is no official recommendation for a waiting period.
- COVID-19 vaccines may be administered without regard to timing of other vaccines.
- In accordance with general best practices, routine administration of all age-appropriate doses of vaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications exist at the time of the healthcare visit.

QUESTIONS

If someone received one dose of J&J as a primary series, then Moderna as a booster, can they get the new booster?

- YES.
- If it has been at least 2 months since their last dose of any monovalent COVID-19 vaccine, they are eligible to receive the new booster.

QUESTIONS

How long should someone wait after being sick with COVID-19 to get a COVID-19 vaccine?

- COVID-19 vaccination is recommended for everyone ages 6 months and older, regardless of a history of symptomatic or asymptomatic SARS-CoV-2 infection.
- Growing epidemiologic evidence indicates that vaccination following SARS-CoV-2 infection further increases protection from subsequent infection and hospitalization, including in the setting of increased circulation of more infectious SARS-CoV-2 strains.
- In addition, **people who recently had SARS-CoV-2 infection may consider delaying a primary series dose or booster dose by 3 months** from symptom onset or positive test (if infection was asymptomatic).

QUESTIONS

Can you administer COVID-19 vaccines with other vaccines?

- YES. COVID-19 vaccines may be administered without regard to timing of other vaccines. In accordance with general best practices, routine administration of all age-appropriate doses of vaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications exist at the time of the healthcare visit.
- Exception: Monkeypox vaccine
 - If monkeypox is received, patients might consider waiting 4 weeks after vaccination to receive a COVID-19 vaccine. This recommendation is due to a slight increased risk of myocarditis/pericarditis.
 - If COVID-19 vaccine is administered first, then a patient is eligible to receive a monkeypox vaccine, the monkeypox vaccine should be given without regards to timing. No minimum interval is necessary.

QUESTIONS

Where can I find this information?

- ALL of the recommendations and guidelines are available on the CDC's website
 - Direct Link: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- Charts with updated guidelines are available on the Immunize Arkansas website.
 - Direct Link: <https://www.immunizear.org/covid-19>

RESOURCES

- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/index.html>